Drug Trial Radar · NCT00877214
Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
Last checked: Nov 19, 2026Latest source record: Aug 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,272
Actual
Start
Apr 1, 2009
Primary completion
Dec 2024
Study completion Dec 2024
Sponsor
- Lead sponsor
- Jurgen BarthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sponsor GmbH
- First posted
- Apr 7, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if an extended maintenance therapy with Rituximab in follicular and a maintenance therapy in other indolent and mantle cell lymphomas has advantages compared to a shorter or no maintenance therapy.
Conditions
- Follicular Lymphomas
- Immunocytomas
- Marginal Zone Lymphomas
- Mantle-Cell Lymphomas
- Lymphocytic Lymphoma
- Non-Hodgkin's Lymphoma
Interventions
RituximabDrug
Follicular Lymphomas: induction therapy with bendamustine + rituximab. If CR or PR: Maintenance therapy with rituximab every 2 months for 4 years Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years
Rituximab / observationDrug
Follicular Lymphomas:induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years (standard) Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: observation (standard)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survivalTime frame: 5 years and ongoing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
StiL Head Office; Justus-Liebig-University
Giessen, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.